Oxford Cannabinoid Technologies announces strategic partnership with Evotec

We are delighted to announce a new INDiGO agreement with Evotec, a leading drug development company, which means that the development of our first cannabinoid medicine to treat chronic pain will advance more quickly. Evotec’s INDiGO programme is an integrated drug development process for accelerating early drug candidates to clinical trial stage. INDiGO increases development speed and optimises the chances of successfully progressing drug candidates to the clinic. This is a hugely significant step on the path to drug development.

Dr Valentino Parravicini, our Chief Scientific Officer, goes into further detail below: 

Video Block
Double-click here to add a video by URL or embed code. Learn more
Previous
Previous

Oxford Cannabinoid Technologies says admission to the OTCQB is a logical next step

Next
Next

Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts